NDLI: Combination therapy in hypertension: A focus on angiotensin receptor blockers and calcium channel blockers.

Please wait, while we are loading the content...

Effect of medical therapy on left ventricular ejection fraction in patients with systolic heart failure and narrow QRS duration with and without ischemic heart disease and left ventricular mechanical dyssynchrony.

Prevalence of complications during implantation and during 38-month follow-up of 1060 consecutive patients with implantable cardioverter-defibrillators.

Prevalence of appropriate management of diabetes mellitus in an academic general medicine clinic.

Practical implications of ACC/AHA 2007 guidelines for the management of unstable angina/non-ST elevation myocardial infarction.

QTc intervals in drug poisoning patients with tricyclic antidepressants and selective serotonin reuptake inhibitors.

The MALAdy of metformin poisoning: Is CVVH the cure?

Etiology and risk factors for developing orthostatic hypotension.

Mechanisms underlying pleiotropic effects of statins.

Eltrombopag (Promacta), a thrombopoietin receptor agonist for the treatment of thrombocytopenia: current and future considerations.

Preadmission use of systemic glucocorticoids and 30-day mortality following bleeding peptic ulcer: a population-based cohort study.

Ramipril-induced generalized pustular psoriasis: case report and literature review.

Racial/ethnic differences in blood pressure control and medication utilization in a cohort of older veterans with dementia.

Incidence, clinical and epidemiological risk factors, and outcome of drug-induced hepatitis due to antituberculous agents in new tuberculosis cases.

A randomized, comparative, multicentric evaluation of atenolol/amlodipine combination with atenolol alone in essential hypertensive patients.

Metastatic pancreatic adenocarcinoma: current standards, future directions.

Private sector contributions to pharmaceutical science: thirty-five summary case histories.

A single supratherapeutic dose of rolofylline does not prolong the QTcF interval in healthy volunteers.

The effects of multiple doses of rolofylline on the single-dose pharmacokinetics of midazolam in healthy subjects.

Premarket clinical evaluation of novel cardiovascular devices: quality analysis of premarket clinical studies submitted to the Food and Drug Administration 2000-2007.

Role of angiotensin-converting enzyme inhibitors in vascular modulation: beyond the hypertensive effects.

The hubris of science: defending the scientific process from political agendas.

Combination therapy in hypertension: A focus on angiotensin receptor blockers and calcium channel blockers.

Year: 2009 Volume: 16

Year: 2008 Volume: 15

Combination therapy in hypertension: A focus on angiotensin receptor blockers and calcium channel blockers.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Meka, Naga Katragadda, Srikanth Cherian, Biju Arora, Rohit R.
Spatial Coverage	United States
Description	Country affiliation: United States Author Affiliation: Meka N ( Department of Cardiology, Rosalind Franklin University, North Chicago VA Medical Center, IL 60064, USA.)
Abstract	Every third adult in the United States has hypertension. Hypertension is a continuous, independent, potent risk factor for cardiovascular events like stroke, myocardial infarction, and heart failure. The blood pressure control achieved with most hypertensives is way below the recommended goal. Recent trials suggest that for nearly half of hypertensive patients, a monotherapy regimen is not adequate to control blood pressure. Investigators recommend from randomized, controlled studies that combination therapy be considered when blood pressure is above the goal of 20/10 mm Hg. In this review we discuss clinical trials that establish the need for combination therapy, with the primary focus on a new combination: calcium channel blockers (CCBs) and angiotensin receptor blockers (ARBs). ARBs and CCBs in combination can complement each other in lowering blood pressure, with a lower incidence of adverse effects, as compared with individual monotherapy components at high doses.
File Format	HTM / HTML
ISSN	10752765
Issue Number	1
Volume Number	17
e-ISSN	15363686
Journal	American Journal of Therapeutics
Language	English
Publisher	Lippincott Williams & Wilkins
Publisher Date	2010-01-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmacology Angiotensin Ii Type 1 Receptor Blockers Therapeutic Use Calcium Channel Blockers Hypertension Drug Therapy Adult Administration & Dosage Adverse Effects Blood Pressure Drug Effects Clinical Trials As Topic Drug Therapy, Combination Humans Epidemiology Physiopathology United States Journal Article Review
Content Type	Text
Resource Type	Article
Subject	Pharmacology Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.

Blood pressure control with angiotensin receptor blocker-based three-drug combinations: key trials.

Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan.

Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension.

Trial watch: dual inhibition shows promise in hypertension.

Managing peripheral edema in patients with arterial hypertension.

Triple combination therapy to improve blood pressure control: experience with olmesartan-amlodipine-hydrochlorothiazide therapy.

The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases.

Efficacy of combination therapy with angiotensin-converting enzyme inhibitor and calcium channel blocker in hypertension.

Combination therapy in hypertension: A focus on angiotensin receptor blockers and calcium channel blockers.

Similar Documents

Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.

Blood pressure control with angiotensin receptor blocker-based three-drug combinations: key trials.

Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan.

Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension.

Trial watch: dual inhibition shows promise in hypertension.

Managing peripheral edema in patients with arterial hypertension.

Triple combination therapy to improve blood pressure control: experience with olmesartan-amlodipine-hydrochlorothiazide therapy.

The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases.

Efficacy of combination therapy with angiotensin-converting enzyme inhibitor and calcium channel blocker in hypertension.

Combination therapy in hypertension: A focus on angiotensin receptor blockers and calcium channel blockers.